Enrolling by InvitationN/Aketamine

Long Term Follow Up KET-PD

Sponsored by Yale University

NCT ID
NCT06164756
Target Enrollment
40 participants
Start Date
2023-10-18
Est. Completion
2025-12-21

About This Study

The purpose of this study is to examine a) the longer-term effects of ketamine for treating depression in Parkinson's disease (PD) and b) the effects of CBT on maintaining the effects of ketamine.

Conditions Studied

Parkinson's DiseaseDepression

Interventions

  • Cognitive Behavior Therapy (CBT)
  • Treatment As Usual (TAU)

Eligibility

Age:40 Years - 80 Years
Healthy Volunteers:No
View full eligibility criteria
Eligibility is determined in the ongoing parent clinical trial (KET-PD trial; NCT04944017, HIC 2000030394).

Study Locations (1)

Yale New Haven Hospital
New Haven, Connecticut, United States

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source